Episentum
2010
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Early Stage VC
LATEST DEAL TYPE
1
INVESTORS
Description
Provider of signal enhancement products for optical biosensors. The company develops technologies that improves the performance and broaden the utility of optical biosensors. It also offers dye-labeling reagents and dye-labeled biomolecules for surface plasmon resonance (SPR) biosensors.
Website
Formerly Known As
Episentec
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Primary Office
- Karins väg 5
- 194 61 Upplands Väsby
- Sweden
+46 072-007 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Episentum’s full profile, request a free trial.
Episentum Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 27-May-2013 | Completed | Startup |
Episentum Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Almi Invest | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Episentum Executive Team (1)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Anders Hanning Ph.D | Chief Executive Officer, President and Board Member |
Episentum Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Allan Asp | Almi Invest | Board Member | 000 0000 | |
| Anders Hanning Ph.D | Episentum | Chief Executive Officer, President and Board Member | 000 0000 | |
| Peter Hassler | Self | Chairman | 000 0000 | |
| Sauli Törmälä | Self | Board Member | 000 0000 |